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Summary
Activation of nuclear transcription factor B (NF-B)
by chemotherapeutic agents was found to protect
cells from apoptosis. In light of its central role in regu-
lating the cellular resistance to apoptotic agents, inhi-
bition of NF-B-mediated gene transcription may sen-
sitize tumor cells to chemotherapeutic agents and
enhance their efficacy. We describe herein a noncyto-
toxic imidazoline scaffold that sensitizes leukemia T
cells to the chemotherapeutic agent camptothecin.
No significant induction of apoptosis was found when
cells were treated with the imidazoline; however, pre-
treatment of cells with this agent resulted in a drastic
enhancement in efficacy of camptothecin (w75-fold).
Elucidation of the potential cellular mechanism re-
vealed that the imidazoline prevents nuclear transloca-
tion of NF-B. These findings indicate that inhibition of
NF-B by this imidazoline may present improved stra-
tegies in the chemotherapeutic treatment of cancer.
Introduction
Apoptosis or programmed cell death is a cellular mech-
anism used to regulate cell number and eliminate dam-
aged or mutated cells [1, 2]. Alterations in apoptotic
pathways can disrupt the delicate balance between cell
proliferation and cell death, leading to a variety of dis-
eases [3, 4]. In many cancers, apoptosis is abnormally
downregulated, either by the mutation of proapoptotic
proteins or by the upregulation of antiapoptotic pro-
teins [5]. Aberrant apoptosis provides an intrinsic sur-
vival advantage to cancer cells, causing growth and
expansion of the tumor as well as resistance to pro-
apoptotic signals such as chemotherapeutic agents [6,
7]. In addition, chemotherapeutic agents may also in-
duce secondary antiapoptotic factors, thereby adding
to this intrinsic resistance to chemotherapy [8–11]. The
combination of these antiapoptotic mechanisms has
resulted in an increased dose intensity of chemothera-
peutics, often without the anticipated improved thera-
peutic results. [12] The search for new chemotherapeu-
tic strategies has therefore shifted to small molecules
that can selectively induce apoptosis in cancer cells or
retard the cellular chemoresistance [13–15]. Strategies
using combinations of inducers of apoptosis and/or in-
hibitors of antiapoptotic factors and traditional chemo-*Correspondence: tepe@chemistry.msu.edutherapeutic drugs may provide an improved alternative
to conventional chemotherapy [14, 16–18].
The mammalian nuclear transcription factor, NF-κB,
is a multisubunit complex involved in the regulation of
gene transcription, including the regulation of apo-
ptosis [19, 20]. Five distinct subunits of NF-κB are
found in mammalian cells, which include NF-κB1 (p105/
p50), NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel
[20]. These subunits can compose a variety of homo-
or heterodimers, which are used to control the specific-
ity and selectivity of certain DNA control elements [21,
22]. In most unstimulated mammalian cells, NF-κB ex-
ists mainly as a homodimer (p50/p50) or heterodimer
(p50/p65) in the cytoplasm in the form of an inactive
complex with the inhibitory protein I-κB (Figure 1).
Many cellular stimuli, including antineoplastic agents
[23–31], viruses (e.g., HIV), cytokines, phorbol esters,
and oxidative stress, result in the IKK-mediated phos-
phorylation of I-κB on serines 32 and 36, followed by
ubiquitinylation and subsequent degradation by the 26
S proteosome [19]. Degradation of I-κB ensures the re-
lease of NF-κB. [32] Upon release, NF-κB translocates
into the nucleus, where the subunits bind with specific
DNA control elements and initiate gene transcription
(Figure 1). Prior to DNA binding, additional protein
phosphorylation events are required for optimal and
specific gene transcription [33–36]. Antiapoptotic genes
such as TRAF1, TRAF2, c-IAP1, c-IAP2, XIAP, and IEX-
1L are directly regulated by NF-κB and abrogate the
apoptotic signals in response to the chemotherapeutic
agents [10, 37].
The antitumor agent camptothecin (CPT) is an alkaloid
isolated from the extracts of the fruit of Camptotheca
acuminata and was identified as a topoisomerase I inhibi-
tor [38, 39]. CPT-11 and several water-soluble analogs
including topotecan have successfully passed clinical
trials in the United States [40]. Camptothecin exhibits
its antitumor activity via the formation of a stable ter-
nary topoisomerase I-DNA cleavable complex [38, 41].
Stabilization of this cleaved DNA complex initiates an
apoptotic signaling pathway, ultimately resulting in cell
death [38, 42]. Concomitant with the initiation of this
apoptotic cell signal, these agents induce antiapoptotic
signaling pathways, which have compromised their effi-
cacy in the clinic [26, 43–45]. This cellular resistance
has been attributed to the activation of antiapoptotic
signaling pathways mediated by several transcription
factors, in particular the nuclear transcription factor,
NF-κB [11, 28, 46].
cDNA microarrays on HeLa cells using all annotated
human genes have been used to establish the associa-
tion between characteristic gene expression patterns
in response to camptothecin [47, 48]. These studies in
HeLa cells provided striking support that administration
of camptothecin resulted in upregulation in a large
number of genes controlled by NF-κB [47]. NF-κB’s me-
diated antiapoptotic response induced by DNA-damag-
ing agents may also result in the induction of cellular
DNA repair mechanisms [49]. Topoisomerase inhibitors
are in this context also considered DNA-damaging
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by Chemotherapeutic Agentsagents, since they exert their cytotoxicity via the stabili- t
czation of a ternary DNA-drug-protein cleavable com-
plex [42]. In addition to the induction of antiapoptotic c
tgene transcription, the topoisomerase I inhibitor camp-
tothecin was found to induce the NF-κB-mediated acti- w
tvation of proto-oncogenes such as c-Myc and cyclin
D1 and indirect deregulation of the retinoblastoma tu- h
imor suppressor protein (Rb protein) [26, 43, 50, 51].
Thus, chemotherapeutic treatment by these agents h
ioften fails as a result of an NF-κB-mediated double
stimulus, causing chemoresistance and favoring un- s
tcontrolled cell growth.
Inhibition of the nuclear translocation of NF-κB t
tblocks the induction of antiapoptotic gene transcription
and was found to sensitize tumor cells to chemothera- c
wpeutic agents and enhance their antitumor efficacy [17,
29, 50, 52, 53]. Baldwin et al. have demonstrated the t
rcontrol of inducible chemoresistance through inhibition
of NF-κB using a mutated form of I-κBα, a natural inhib- 3
iitor of NF-κB (Figure 1) [50]. In another study, Piette et
al. showed that the overexpression of I-κBα/mutated t
cI-κBα regulated the cytotoxicity caused by campto-hecin [54]. These pioneering studies illustrated the
linical potential of NF-κB inhibitors in combination
hemotherapy. There are numerous natural and syn-
hetic inhibitors of NF-κB reported in the literature [55],
hich include many antioxidants such as pyrrolinedi-
hiocarbamate or PDTC, [56] kinase inhibitors such as
ymenialdisine and analogs [57–61], SC-514 [62], inhib-
tors of I-κB degradation such as the proteosome in-
ibitors lactacystin [63–65] and PS-341 [66], and IKK
nhibitors such as the sesquiterpene lactones repre-
ented by parthenolide [67, 68]. Even though many of
hese agents indicate inhibition of the antiapoptotic
ranscription factor, enhancement of chemotherapeu-
ics has been limited. The most successful example of
ombination therapy using chemotherapeutic agents
ith NF-κB inhibitors has been illustrated by the pro-
easome inhibitor PS-341 (bortezomib), which is cur-
ently in phase II clinical trials in the US [53, 69]. PS-
41 inhibits the nuclear translocation of NF-κB via the
nhibition of the 26 S proteasome-mediated degrada-
ion of I-κB (Figure 1). Since PS-341 exhibits significant
ell cytotoxicity, it may be used as a single agent or in
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providing a more than additive apoptotic response
[66, 70].
We describe herein a noncytotoxic agent that drasti-
cally enhances the activity of camptothecin in leukemia
T cells. This class of NF-κB inhibitors is structurally dif-
ferent from any reported NF-κB inhibitor and unique
with respect to its insignificant toxicity and remarkable
ability to enhance the anticancer efficacy of the chemo-
therapeutic agent camptothecin. The agent was prepared
via our recently reported diastereoselective multicom-
ponent one-pot synthesis of imidazolines (Figure 2) [71,
72]. A large library of imidazoline scaffolds was pre-
pared via this silicon-mediated cycloaddition reaction
and evaluated for biological activity. Upon screening of
these agents, we found that the imidazoline 1 exhibited
no apparent cytotoxicity; however, further investiga-
tions revealed that this agent drastically enhanced the
level of apoptosis induced by chemotherapeutics. Even
though micromolar concentrations of compound 1 did
not induce any apoptosis when used as a single agent,
it was found to enhance the anticancer efficacy of the
anticancer agent camptothecin approximately 75-fold
at 100 nanomolar concentration. Investigation into its
potential mode of action revealed that the imidazoline
blocks the nuclear translocation of NF-κB via the inhibi-
tion of phosphorylated I-κB degradation. The inhibitionFigure 2. Synthesis of Imidazoline 1 and Proposed Rationale for
Diastereoselectivity of Compound 1
(A) Synthesis of imidazoline 1. a: benzoyl chloride, NaOH (aq), Et2O,
overnight; b: EDCI, CH2Cl2, 2 hr, room temperature, 68% overall;
c: TMSCl, benzylamine, benzaldehyde, CH2Cl2, reflux 4 hr, room
temperature, overnight, 65%.
(B) Proposed rationale for diastereoselectivity of compound 1.of NF-κB by compound 1 may provide a potential ratio-
nale for its enhancement of CPT-induced apoptosis.
These findings illustrate that this class of antiapoptotic
inhibitors might provide an improved therapeutic strat-
egy in the treatment of cancer.
Results and Discussion
Synthesis of Imidazoline 1
The imidazoline scaffold was prepared via a novel sili-
con mediated 1,3-dipolar cycloaddition reaction [71,
72]. The low molecular weight scaffold contains a four-
point diversity applicable to alkyl, aryl, acyl, and hetero-
cyclic substitutions. After screening a small number of
Lewis acid, we found that TMSCl promotes the reaction
of oxazolones and imines to afford the imidazolines
scaffolds in good yields as single diastereomers (Fig-
ure 2).
Compound 1 was isolated as a single diastereomer,
and the diastereoselectivity appears to primarily arise
from the steric interaction of the bulky silyl group of the
azlactone and the phenyl moiety of the imine (Figure 2).
Sensitization of Cancer Cells toward Camptothecin
The imidazolines were evaluated for their ability to en-
hance the activity of camptothecin (CPT) in cancer cells
by evaluating the level of apoptosis induced by camp-
tothecin in the presence and absence of compound 1.
Induction of apoptosis is the hallmark of most chemo-
therapeutic agents, including camptothecin [38, 73].
The level of apoptotic cell death was measured using
a caspase-based screen. Caspase activation plays a
central role in the execution of apoptosis via the pro-
teolytic cleavage of multiple protein substrates by cas-
pases 3, 6, and 7 [74–76]. The level of induction of
apoptosis in cells was quantified using a commercially
available Apo-ONE assay, which takes advantage of
caspase 3/7 activity. Treatment of the CEM leukemia T
cells with compound 1 did not induce significant
amounts of apoptosis (tested up to 10 M for 48 hr by
Apo-ONE as well as by cell count; data not shown). The
imidazoline 1 was subsequently screened for its ability
to enhance apoptosis induced by the chemotherapeu-
tic, camptothecin [40].
Enhancement of CPT-induced apoptosis in CEM cells
was first investigated at concentrations of %10 nM
CPT, at which CPT has been reported to cause DNA
aberrations but no significant levels of apoptosis in leu-
kemia cells [77]. Figure 3 illustrates the effect of the
imidazoline on CEM cells when incubated with CPT (10
nM) over a 48 hr time period. Treatment of the cells
with compound 1 (10 nM) had no effect on the level of
apoptosis. Treatment of the cells with 10 nM CPT re-
sulted in some cell death starting after 12 hr of drug
treatment. Combination treatment of the noncytotoxic
imidazoline 1 (10 nM) with CPT (10 nM) resulted in com-
plete apoptotic cell death after 48 hr.
Additional experiments were performed in order to
quantify the enhancement of the apoptotic signal in
leukemia cells. Briefly, the study was divided into two
sets of experiments, one involving continuous expo-
sure of the agents to the cells, and another subjecting
Chemistry & Biology
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Camptothecin by Imidazoline 1, Measured
over 48 hr, and Comparison of Cytotoxic
Concentration
(A) Data are reported as an average of two
independent experiments (error margins are
included). The figure illustrates cell death
through apoptosis as a function of time for
cells alone (dark blue squares), imidazoline
only (10 nM, pink squares), CPT (10 nM, light
blue triangles), and CPT (10 nM) in the pres-
ence of imidazoline (10 nM) (red circles).
(B) Comparison of cytotoxic concentration
causing 95% cell cytotoxicity in continuous
exposure and washed cells as averages of
two independent experiments. NT, not tested.the cells to an initial exposure of the drug, followed by 0
cremoval of drug and supplementation with fresh media.
Cells were preincubated with 1, 10, and 100 nM con- c
acentrations of the imidazoline followed by exposure to
a titration range of CPT concentrations. Various time w
Ppoints were obtained and the data were analyzed. The
data are summarized in Figure 4 and illustrate the effect m
mon the CC95 for camptothecin on cells pretreated with
imidazoline (for the complete data set, see Supplemen- z
mtal Figure S1).
The CC95 of CPT was decreased 75.08-fold when the
ccells were pretreated with 0.1 M imidazoline for 1 hr.
This fold enhancement was reduced to 29.1-fold en- d
shancement of efficacy when the amount of imidazoline
was decreased to 1 nM. As anticipated, the continuous
exposure resulted in an overall higher cell cytotoxicity P
due to a longer exposure time. When the cells were I
washed with 1× PBS after 1 hr of camptothecin treat- t
ment, the fold enhancement dropped to 20.9-fold of w
CPT-induced cell death (CC95). Similar potentiation was κ
seen with pretreatment of ALLN followed by campto- m
thecin treatment (see Supplemental Figure S2). Post- p
treatment of CPT-exposed cells with the imidazoline af- i
ter 1, 2, or 4 hr resulted in no enhancement of apoptosis e
over a 48 hr time period, suggesting the possible inhibi- N
tion of an antiapoptotic event induced by CPT (data
not shown). N
A
aCell Death Determined by Trypan Blue Exclusion
Parallel to the Apo-ONE assay, cells were counted by g
cthe trypan blue exclusion method to determine the
number of viable cells. Cells were preincubated with I.1 M, 0.01 M, and 1 nM imidazoline, then various
oncentrations of camptothecin were added, and the
ells were incubated for 0, 24, and 48 hr. Well-mixed
liquots of these cell cultures were subsequently mixed
ith equal volumes of 0.04% trypan blue dye in 1 ×
BS and counted on a hemacytometer under the
icroscope. The results clearly confirmed the enhance-
ent of camptothecin activity in the presence of imida-
oline, as seen in the Apo-ONE assays (see Supple-
ental Figure S3).
Combination treatment of compound 1 with varying
oncentrations of CPT (10–0.1 M) caused a strong in-
uction of apoptosis, resulting in a dose-dependent re-
ponse.
athway of Apoptotic Modulation
n order to determine the potential molecular pathway
hrough which the imidazoline modulates apoptosis,
e evaluated its ability to inhibit CPT induction of NF-
B activation. Inhibition of the NF-κB signaling cascade
ay occur at several different steps in its activation
athway (Figure 1). In order to determine where the im-
dazoline intersected the NF-κB activation pathway, we
xamined the effect of imidazoline 1 on CPT-induced
F-κB activation in each of the steps shown in Figure 1.
F-B Activation by Camptothecin
ctivation of NF-κB by chemotherapeutic agents such
s camptothecin has been well documented by several
roups in different cell lines, including CEM leukemia T
ells [26, 43, 44]. The stabilization of a topoisomerase
-DNA cleavable complex by camptothecin activates cell
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Lane 1, NF-κB consensus oligonucleotide (0.16 pmol/λ); lane 2, NF-
κB consensus oligo (0.16 pmol/λ) + nuclear extract (TNF-α); lane 3,
NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract (TNF-α + p65
antibody); lane 4, NF-κB consensus oligo (0.16 pmol/λ) + nuclear ex-
tract (unactivated); lane 5, NF-κB consensus oligo (0.16 pmol/λ) +
nuclear extract (10 M CPT); lane 6, NF-κB consensus oligo (0.16
pmol/λ) + nuclear extract (10 M CPT) + p65 antibody; lane 7, NF-κB
consensus oligo (0.16 pmol/λ) + nuclear extract (1 M CPT); lane 8,
NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract (0.1 M CPT);
lane 9, NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract (0.01
M CPT); lane10, NF-κB consensus oligo (0.16 pmol/λ) + nuclear ex-
tract (1 nM CPT); lane 11, NF-κB consensus oligo (0.16 pmol/λ) +
nuclear extract (0.1 nM CPT). All incubations with CPT were per-
formed for 2 hr. The positive control with TNF-α was incubated for
15 min.survival signaling pathways mediated by the nuclear tran-
scription factor NF-κB [26, 43, 44, 49]. The activation of
NF-κB by camptothecin was confirmed in CEM cells
using an EMSA assay [43]. The cellular nuclei were iso-
lated and evaluated for NF-κB-DNA binding utilizing the
fluorescent-labeled NF-κB DNA consensus sequence.
TNF-α activation was used as a positive control (Figure
4, lane 2). The NF-κB/DNA complex was unambigu-
ously identified by treating the nuclear extract with a
NF-κB p65 antibody following TNF-α activation and
CPT activation (Figure 4, lanes 3 and 6, respectively).
Treatment of the nuclear extract with the p65 antibody
resulted in a significant decrease in NF-κB/DNA binding
and the formation of a supershift of the complex (lanes
3 and 6). As a negative control, cells were left unacti-
vated and the nuclear extracts were exposed to the NF-
κB consensus sequence, resulting in only a basal back-
ground level of NF-κB-DNA binding (lane 4). Treatment
of the CEM cells with camptothecin concentrations
ranging from 10 M to 0.1 nM (Figure 4, lanes 5 and 7–
10) illustrated a significant amount of NF-κB/DNA bind-
ing due to NF-κB activation in a concentration-depen-
dent manner.
Activation of NF-κB is transient and depends on ex-
posure time. This was confirmed by treating CEM cells
at log phase with 10 M camptothecin or DMSO at 30
min and 1, 2, 4, 6, 14, and 24 hr (see Supplemental
Figure S4). Maximal NF-κB activation was at 2 hr and
decreased after 4 hr, confirming a post-induction self-
repression loop during the early hours of incubation
with camptothecin consistent with earlier reports [43].
Induction of NF-κB activation can proceed via a wide
range of signaling pathways [78, 79]. Thus, inhibition of
NF-κB activation can proceed via the mediation of
many different pathways [55]. Modulators of thesepathways may therefore act as general activation inhib-
itors, whereas others may inhibit specific induction
pathways [55]. In order to investigate whether the im-
idazoline 1 inhibits the specific pathway of campto-
thecin-induced NF-κB activation, we examined the inhi-
bition of camptothecin-induced NF-κB-DNA binding in
the presence of compound 1. CEM cells were treated
with various concentrations of imidazoline 1 30 min
prior to treatment by camptothecin (1 M). Pyrrolidine
dithiocarboxylic acid (PDTC) is a nonselective NF-κB
inhibitor and was used as a positive control. After a 2
hr incubation period, the nuclei were isolated and
treated with the labeled κB consensus sequence. As
illustrated in Figure 5, the addition of imidazoline 1 in-
hibited camptothecin-induced NF-κB-DNA binding in a
dose-dependent manner. Control lanes included DNA
only (lane 1), TNF-α-activated NF-κB (lane 2), TNF-α-Figure 5. Inhibition of CPT-Activated NF-κB Binding by Imidazoline 1
Using EMSA
Lane 1, κB consensus oligonucleotide (0.16 pmol/λ); lane 2, NF-κB
consensus oligo (0.16 pmol/λ) + nuclear extract (TNF-α); lane 3, NF-
κB consensus oligo (0.16 pmol/λ) + nuclear extract (TNF-α) + p65
antibody; lane 4, NF-κB consensus oligo (0.16 pmol/λ) + nuclear ex-
tract (no activation); lane 5, NF-κB consensus oligo (0.16 pmol/λ) +
nuclear extract (1.0 M CPT); lane 6, NF-κB consensus oligo (0.16
pmol/λ) + nuclear extract (1.0 M CPT) + antibody p65; lane 7, NF-κB
consensus oligo (0.16 pmol/λ) + nuclear extract (1.0 M CPT + 1 M
PDTC); lane 8, NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract
(1.0 M CPT + 1.0 M imidazoline 1); lane 9, NF-κB consensus oligo
(0.16 pmol/λ) + nuclear extract (1.0 M CPT + 0.1 M imidazoline 1);
lane 10, NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract (1.0
M CPT + 0.01 M imidazoline 1); lane 11, NF-κB consensus oligo
(0.16 pmol/λ) + nuclear extract (1.0 M CPT + 1.0 nM imidazoline 1);
lane 12, NF-κB consensus oligo (0.16 pmol/λ) + nuclear extract (1.0
M CPT + 0.1 nM imidazoline 1). All incubations with CPT were per-
formed for 2 hr. The positive control with TNF-α was incubated for
0.5 hr.
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oprovided a supershift (lane 3), and the unactivated con-
trol (lane 4). Treatment of the cells with camptothecin w
tresulted in the activation of NF-κB, as indicated by the
strong band of the NF-κB-DNA complex (lane 5). Inhibi- 
stion of DNA binding in the presence of the non-selec-
tive NF-κB inhibitor PDTC resulted in reduced binding t
as anticipated (lane 7). A similar reduction in campto-
thecin-induced NF-κB-DNA binding resulted upon treat- E
ment of imidazoline 1 (concentrations ranging from 10 L
M to 10 nM), as illustrated in lanes 8–12. Comparison c
of lane 5 (activated by 1 M CPT) with lane 8 (activated d
by 1 M CPT + 1 M compound 1) clearly indicates a I
significant decrease in NF-κB-DNA complex formation. q
e
EInhibition of Camptothecin-Induced Nuclear
Translocation of NF-B by Imidazoline 1 c
mThe previously described EMSA studies indicate that
imidazoline 1 inhibits the binding of NF-κB to its con- t
psensus sequence. This may be due to a direct inhibition
of DNA binding or to a decrease in the amount of NF- p
pκB in the nucleus. We therefore investigated the ability
of compound 1 to inhibit the nuclear translocation of t
aNF-κB using a p65 sandwich ELISA assay (Figure 6).
Activation of NF-κB was carried out for a period of 0.5 a
ghr for TNF-α and 2 hr for camptothecin, after which the
nuclear extracts were isolated. TNF-α activation of NF- t
lκB was used as positive control, and the level of trans-
located p65 was normalized to 100%. The negative c
icontrol included the level of nuclear p65 without activa-
tion [57, 58]. Treatment of the cells with TNF-α or CPT I
d(1.0 M) resulted in a significant increase in nuclear NF-
κB, as illustrated in Figure 6 (first and third columns, c
lrespectively). Pretreatment of the cells with the nonse-
lective NF-κB inhibitor PDTC (5 M) indicated a signifi- t
Icant inhibition of nuclear translocation after CPT activa-
tion (fourth column). Pretreatment of the cells with
aimidazoline 1 30 min prior to activation also resulted in a
significant inhibition of translocation (fifth column). Vari- k
pous concentrations ranges of the imidazoline (1–100 nM)
resulted in inhibition of translocation (Figure 6). Similar t
sresults were obtained with HeLa cells activated with
TNF-α (Figure 6) as well as Jurkat cells activated with N
ePMA/PHA (data not shown). These findings indicate
that imidazoline 1 inhibits the nuclear translocation of o
cNF-κB at the nanomolar level.
t
dInhibition of Kinase Activity
TWe have demonstrated that imidazoline 1 inhibits the
Stranslocation of NF-κB across the nuclear membrane in
tresponse to stimulation by camptothecin. The translo-
tcation of NF-κB requires the phosphorylation and sub-
isequent degradation of its inhibitory protein I-κB by the
26 S proteosome, resulting in the liberation of NF-κB
[81]. Thus, the effect of the imidazoline on I-κB phos- I
Tphorylation and degradation was investigated. We first
evaluated the imidazoline for its effect on the phos- T
κphorylation of the inhibitory protein I-κB by its endoge-
nous kinases IKKα and IKKβ (data not shown) [26, 79, b
l80]. No inhibition of kinase activity was observed
(tested at 10 M). Alternatively, inhibition of NF-κB w
gtranslocation may be the result of the upstream inhibi-
tion of kinase activity in a variety of kinase pathways. ce therefore evaluated imidazoline 1 for its inhibition
f the several kinases either related to the NF-κB path-
ay or other apoptotic signaling pathways. No inhibi-
ion of any kinase activity was detected (tested up to 10
M concentrations of the imidazoline). Based on these
tudies, it is unlikely that imidazoline 1 inhibits nuclear
ranslocation via the inhibition of kinase activity.
ffect of Imidazoline 1 on I-B Phosphorylation
iberation of the NF-κB subunits from the NF-κB/I-κB
omplex is required for efficient translocation and is
ependent on the degradation of the inhibitory protein
-κB. The CPT-induced phosphorylation and subse-
uent degradation of I-κB was evaluated in the pres-
nce and absence of the imidazoline 1 using a pS32
LISA on the cellular cytoplasmic extracts. A time
ourse experiment using 2 M CPT indicated that 60
in was the optimum time period for I-κB phosphoryla-
ion (see Supplemental Figures S5 and S6). Cyto-
lasmic extracts from CPT-treated cells with or without
retreatment with imidazoline were analyzed for phos-
horylation at ser-32 and ser-36 (Figure 7). ALLN (N-ace-
yl-Leu-Leu-norleucinal), a proteasome inhibitor [82, 83],
nd parthenolide, an IKK inhibitor [67, 68], were used
s controls to mark the two steps involved in I-κB de-
radation leading to NF-κB translocation and gene
ranscription. Parallel to the pS32 ELISA, the total I-κB
evels were measured to accurately determine the per-
ent phosphorylation. As anticipated, the proteasome
nhibitor ALLN shows accumulation of phosphorylated
-κB, whereas the IKK kinase inhibitor indicated a
ecrease in phosphorylation. Upon pretreatment of the
ells with imidazoline 1, accumulation of phosphory-
ated I-κBα was observed. The values were normalized
o the total amount of I-κB, resulting in an IC50 value
-κB phosphorylation of 0.19 M.
Similar experiments were performed using TNF-α to
ctivate the leukemia cells. Both TNF-α and CPT are
nown to activate NF-κB by I-κB degradation following
hosphorylation at ser-32 and ser-36 in CEM cells, al-
hough with varying kinetics [54]. Consistent with these
tudies, we found that the imidazolines inhibited the
F-κB signaling pathway in TNF-α-activated cells more
ffectively than with CPT, illustrated by an IC50 value
f 2.1 nM (see Supplemental Figure S6). These studies
learly demonstrate that imidazoline 1 inhibits nuclear
ranslocation of NF-κB via the inhibition of I-κB degra-
ation of TNF-α as well as CPT-activated CEM cells.
his suggests that the imidazoline may target the 26
proteosome or the ubiquitinylation of I-κB. Studies
oward the identification of the potential molecular
arget and its binding interactions are actively ongoing
n our lab.
nhibition of CPT-Induced NF-B
ranscription by Imidazoline 1
o demonstrate the ability of imidazoline 1 to affect NF-
B mediated gene transcription, we evaluated the inhi-
ition of NF-κB-mediated luciferase production using a
uciferase reporter assay. HeLa cells were transfected
ith 6× κB driven reporter gene pNF-κB-Luc (Strata-
ene) and were activated with TNF-α (10 ng/l) or
amptothecin (3 M) in the presence and absence of
Enhancing the Efficacy of Camptothecin
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sured by p65 ELISA Assay of Compound 1 in
CEM and HeLa Cells with Camptothecin and
TNF-α
All values have been normalized to the posi-
tive control to show percentage of transloca-
tion, and the data are reported as an average
of two independent experiments.imidazoline 1, parthenolide, ALLN, or DMSO control,
and luciferase production was assayed using the Dual-
Glo reporter assay. A constitutively activated plasmid
pFC-MEKK was used as a positive control for transfec-
tion. pCIS-CK was used as the negative control for the
κB-driven reporter gene. pRL-TK was used as a core-
porter. The imidazoline inhibited the NF-κB-induced
transcription by 52% and an EC50 value of 0.95 M
when cells were activated by TNF-α. The imidazoline
inhibited the CPT induced NF-κB transcription by up to
35%, providing an EC50 value of 9.8 M (Supplemental
Figure S9).
Luciferase Enzyme Assay
To confirm the inhibition of NF-κB-mediated luciferase
production by imidazoline 1 and the luciferase enzyme
itself, we incubated purified luciferase enzyme with var-
ious concentrations of imidazoline and vehicle at 0°Cfor 1 hr. These were then analyzed for luciferase activ-
ity. Imidazolines did not appear to effect the activity of
the enzyme (see Supplemental Figure S8).
Significance
Antitumor drugs exert their antitumor activity via the
initiation of apoptotic signaling pathways, ultimately
resulting in cell death. Concomitant with the initiation
of this apoptotic cell signal, many chemotherapeutic
agents, including camptothecin, induce antiapoptotic
signaling pathways, which have compromised the ef-
ficacy of these antitumor agents in the clinic. Inhibi-
tion of the antiapoptotic transcription factor, NF-B,
retards this cellular resistance. We discovered a class
of nontoxic agents that drastically enhance the anti-
tumor efficacy of the chemotherapeutic agent camp-
tothecin. The imidazoline 1 was found to sensitize
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1696Figure 7. Relative Amounts of Phosphorylated
I-κB at Serine 32 and Serine 36
All values were normalized to maximum accu-
mulation seen in Alln control, and data are re-
ported as the average of two independent ex-
periments. Activation of NF-κB was initiated
using 2 M camptothecin, and 50 M Alln and
50 M parthenolide were used as controls for
proteasomal and IKK inhibition, respectively.
The control for parthenolide shows a negative
bar due to its cell cytotoxicity over the course
of the experiment.tleukemia cells at nanomolar concentrations to camp-
ftothecin and drastically enhance the level of campto-
athecin-induced apoptosis. Combination therapy of
iCEM cells with camptothecin and the imidazoline 1 w
provided w75-fold enhancement of efficacy after 48 t
chr. The ability of the imidazoline to enhance the apo-
fptotic events initiated by camptothecin may proceed
via the inhibition of the NF-B signaling pathway. In-
hibition of the NF-B pathway was found to occur via E
Ethe inhibition of degradation of NF-B inhibitory pro-
Ttein I-B. These findings are consistent with the lack
mof enhancement of CPT-induced apoptosis in the post-
btreatment of cells with compound 1. These studies
Hindicate that combination therapy of classical anti- w
cancer agents with small molecule NF-B inhibitors p
ohas the potential to target chemoresistance and pro-
tvides a potential new strategy to treat chemoresistant
ttumors. Work toward a detailed molecular mechanism
pand the clinical potential of these agents is currently
o
under investigation in our laboratory. (
w
Experimental Procedures s
A
Chemicals and Antibodies 
Camptothecin and TNF-α were purchased from Sigma. ALLN was 6
purchased from Calbiochem. Parthenolide and monoclonal anti- v
body for supershifts for p65 were purchased from Santacruz Bio- o
technology. HeLa cells were a kind gift from Prof. John LaPres, a
Dept. of Biochemistry and Molecular Biology, Michigan State Uni- g
versity. t
Apoptosis Assay with Apo-ONE
CEM cells (CCRF-CEM; Amer. Type Culture Collection, Rockville, I
TMD) were grown in RPMI-1640 media (Gibco-BRL, Rockville, MD)
supplemented with 10% fetal bovine serum, penicillin (614 ng/ml), n
(streptomycin (10 g/ml), and HEPES buffer (pH 7.2) at 37°C, 5%
CO2. DMSO was used as the vector for all drugs and was added in w
pthe control experiments. Cell cultures were treated with 0.1 M,
0.01 M, or 1 nM of the imidazoline 1 and allowed to incubate at o
h37°C, 5% CO2 atmosphere for 30 min. Camptothecin was added at
concentrations 50 M, 1 M, 0.3 M, 0.1 M, 0.03 M, 0.01 M, 3 p
TnM, 1 nM, or 0.3 nM and further incubated. An aliquot was transfer-
red to a 96-well plate at various time points, 0, 6, 12, 24, and 48 hr, q
and mixed with an equal volume of Apo-ONE homogenous cas-
pase 3/7 assay (Promega Corporation) reagent. The contents ofhe plate were gently mixed and allowed to incubate for 1 hr. The
luorescence of each well was then measured on a Molecular Im-
ger FX Pro at 532 nm. All reported data are the average of two
ndependent experiments unless otherwise indicated. The data
ere analyzed using GraphPad prism. Data were normalized be-
ween maximum and minimum cell death relative to the respective
ontrol sets, and CC95 values were calculated using the equation
or the sigmoidal curve for variable slope.
MSA Assay for NF-B-DNA Binding
MSA assay for NF-κB-DNA binding: CEM cells (CCRF-CEM; Amer.
ype Culture Collection, Rockville, MD) were grown in RPMI-1640
edia (Gibco-BRL, Rockville, MD) supplemented with 10% fetal
ovine serum, penicillin (614 ng/ml), streptomycin (10 g/ml), and
EPES buffer (pH 7.2) at 37°C, 5% CO2. Cells (1.6 × 106 cells/ml)
ere subsequently treated with various concentrations of com-
ound 1 for 30 min at 37°C and 5% CO2 followed by TNF-α (0.4 pg)
r camptothecin (Sigma-Aldrich) (1.0 M) stimulation for an addi-
ional 30 min or 2 hr, respectively. The cells were harvested by cen-
rifugation, washed in ice-cold PBS, and the nuclear extracts were
repared as previously described [52]. The protein concentration
f the extracts was determined according to the Bradford method
1976) with BioRad reagents. Nuclear extracts (20 g total protein)
ere incubated for 20 min at room temperature with a double-
tranded Cy3-labeled NF-κB consensus oligonucleotide, 5#-AGTTG
GGGGACTTTC CCAGGC-3# (0.16 pmol). The binding mixture (25
l) contained 10 mM HEPES-NaOH (pH 7.9), 4 mM tris-HCl (pH 7.9),
.0 mM KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.3 mg/ml bo-
ine serum albumin, and 1 g poly (dI.dC). The mixture was loaded
n a 4% polyacrylamide gel prepared in 1× Tris borate/EDTA buffer
nd electrophoresed at 200 V for 20 min. After electrophoresis, the
el was analyzed using a phosphorimager (Biorad FX plus) for de-
ection of NF-κB-DNA binding.
nhibition of Translocation with p65-ELISA Assay
he quantity of p65/p50 heterodimer that had translocated into the
ucleus was measured using a NF-κB p65 sandwich ELISA assay
Imgenex Corp.). CEM cells were grown to 1.6 × 106 cells/ml and
ere subsequently treated with various concentrations of the com-
ound 1 for 30 min at 37°C and 5% CO2 followed by TNF-α (0.4 pg)
r camptothecin (1.0 M) stimulation for an additional 30 min or 2
r, respectively. The cells were harvested and nuclear extracts were
repared as previously described by Dignam and coworkers [84].
he NF-κB p65 sandwich ELISA assay was used to monitor and
uantify p65 translocation into the nucleus according to the manu-facturer’s protocol. Results were read on Biorad’s Microplate
Benchmark reader at 405 nM.
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CEM cells (CCRF-CEM; Amer. Type Culture Collection, Rockville,
MD) were grown in RPMI-1640 media (Gibco-BRL, Rockville, MD)
supplemented with 10% fetal bovine serum, penicillin (614 ng/ml),
streptomycin (10 g/ml), and HEPES buffer (pH 7.2) at 37°C, 5%
CO2. Cells (1.6 × 106 cells/ml) were subsequently treated with vari-
ous concentrations of compound 1, ALLN (50 M), parthenolide (50
M), or vehicle (DMSO) for 1 hr at 37°C and 5% CO2 followed by
TNF-α (0.4 pg) or camptothecin (Sigma-Aldrich) (2.0 M) stimulation
for an additional 4 min or 1 hr, respectively. The cells were harvested
by centrifugation, washed in ice-cold PBS, and the cytoplasmic
extracts were prepared as described by the manufacturer’s proto-
col. The protein concentration of the extracts was determined ac-
cording to the method of Bradford (1976) with BioRad’s Bradford
reagent. Extracts were diluted and subjected to I-κBα (pS32) and
I-κBα (total) ELISA (Biosource International, CA) to measure and
quantify the effect of imidazoline on the phosphorylation status of
I-κBα. Results were read on Biorad’s Microplate Benchmark reader
at 450 nM.
Inhibition of Kinase Activity
The in vitro kinase assay was conducted as follows: compound 1
was tested in vitro against the kinases AMPK, Axl, Blk, CDK2/cyclinE,
CDK5/p35, c-RAF, Fes, Flt3, Fyn, IGF-1R, IR, JNK1α1, JNK2α2, JNK3,
Lck, Lyn (human), MAPK1, MAPK2 (human), MEK1, MKK4, MKK6,
MKK7b, MSK1, p70S6K, PDK1, PAK2, PKA (human), PKBβ, PKCα,
PKCy, PKCdelta, PKC, PKCmu, SGK, Yes, Syk, TrkB, and ZAP-70 by
Upstate, UK using a kinase profiler assay according to the manu-
facturer’s protocol. Briefly, in a final volume of 25 l, the kinase
was incubated with the desired buffer and the required polypeptide
substrate in the presence of 10 mM magnesium acetate and γ-33P-
ATP (10 M). After incubation for 40 min at room temperature, the
reaction was stopped by the addition of 3% H3PO4 (5 l). Ten mi-
croliters of the reaction was then spotted on a P30 filtermat,
washed three times in 75 mM H3PO4, and finally in methanol. Sam-
ples were then dried and signals were counted on a scintillation
counter.
Inhibition of NF-B-Mediated Transcription in HeLa Cells
Transient transfections were performed using lipofectamine 2000.
Briefly, 0.8 g of plasmid DNA was combined with 1.5 l lipofec-
tamine 2000 (Invitrogen). The mixture was incubated at room tem-
perature for 20 min and mixed with the cells without serum. Cells
were transfected for 5 hr at 37°C in 5% CO2. Cells were allowed to
grow in complete medium for 15 hr in 5% CO2. Various treatments
with various concentrations of imidazoline 1, parthenolide (50 M),
or ALLN (50 M) were performed for 1 hr followed by a treatment
with TNF-α (10 ng/l) or camptothecin (3 M) for 5 hr or 10.5 hr,
respectively. Cells were washed with 1× PBS. Washed cells were
assayed for luciferase production using the manufacturer’s proto-
col for both luciferase as well as renilla luciferase (coreporter) using
the Dual-Glo reporter assay (Promega). The results were read on a
Veritas microplate luminometer (Turner Biosystems, CA) as relative
light units. Values from the luciferase activity were normalized to
those with renilla luciferase.
Supplemental Data
Supplemental Data including ten figures are available at http://
www.chembiol.com/cgi/content/full/11/12/1689/DC1/.
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